You are here
MediPharm Labs Corp. Receives Sales Licence from Health Canada
TORONTO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (TSXV: LABS) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. The Sales Licence relates to the Company’s wholly-owned laboratory and manufacturing facilities in Barrie, Ontario.
“This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.
A first-mover in cannabis extraction and purification in Canada, MediPharm Labs has invested in an expert team, customized state-of-the-art technology, proprietary methodologies and purpose-built facilities to deliver pharmaceutical-grade and precisely dosable cannabis oils and cannabis concentrates for advanced derivative products. Purified cannabis concentrates have emerged as a preferred basis for consumption and are also the critical elements for isolates and infused products for both the medical and adult use markets where legal globally. MediPharm Labs has been actively building an inventory of specialized cannabis concentrates and isolates in anticipation of receiving its licence, to serve both the medical cannabis and adult-use markets in Canada.
After having obtained its Sales Licence from Health Canada, MediPharm Labs is positioned to fulfill its role in the Canadian cannabis supply chain by delivering advanced oil strategies to its previously announced, innovative and well-established industry partners:
• MediPharm Labs has one of only 32 supply agreements with the Ontario Cannabis Stores
• The Company has signed four multi-year cannabis concentrate program agreements with partner licensed cultivators:
- 3-year agreement with Emerald Therapeutics Inc. (TSXV: EMH – OTCQX: EMHTF) as announced on October 10, 2018
- 3-year agreement with INDIVA Limited (TSXV: NDVA) as announced on September 4, 2018
- 1-year agreement with Bonify (6779264 Manitoba Inc.) as announced on August 2, 2018
- 3-year agreement with James E. Wagner Cultivation Corp (TSXV: JWCA) as announced July 31, 2018
• MediPharm Labs has a 1,200 kg supply agreement with UP Cannabis Inc. (TSXV: HIP) as announced on September 24, 2018
• Through JV “Garden Variety”, the Company expects to supply four future retail stores in Manitoba that have received provincial approval for bricks and mortar stores as announced on August 22, 2018
MediPharm Labs has completed the purification and production of over 180,000 g of cannabis extract.
MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification. MediPharm Labs currently operates one of the largest cannabis concentrate manufacturing facilities in Canada and is built to cGMP (current Good Manufacturing Practices) and ISO standards. Leveraging MediPharm Lab’s proprietary pharmaceutical manufacturing expertise, the Company currently has Phase 1 capacity to process over 100,000 kg of dry cannabis per year. With Phase 2 funded and expected to be completed by the end of Q2 2019, the Company anticipates that its processing capacity will more than double to up to 250,000 kg annually upon the completion of such expansion.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d4559661-f73d-4ed5-84d8-1ad3f4502eaf
About MediPharm Labs Corp.
MediPharm Labs, through its subsidiary, is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs, through its subsidiary, provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand.
MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
For additional information, please see the Company’s website at www.medipharmlabs.com or contact:
Pat McCutcheon, CEO and President of MediPharm Labs
Phone: 705-719-7425 ext. 216
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, the Company’s joint venture in Manitoba, the expected completion date of the Company’s expansion, anticipated processing capacities, and operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.